Emblem Shareholders to Vote on Aleafia Health Merger at Special Meeting on March 6, 2019: Emblem Corp. (TSXV: EMC, OTCQX: EMMBF) announces that the Ontario Superior Court of Justice (Commercial List) granted the Company’s motion for an interim order authorizing various matters, including the mailing of a management information circular and the holding of the special meeting of Emblem shareholders to be held on Wednesday March 6, 2019 at 10:30 a.m. (Toronto time) at the offices of Dentons Canada LLP, 77 King Street West, Suite 400, Toronto, Ontario, M5K 0A1.
The Meeting will be held to consider the previously announced proposed arrangement involving Emblem and Aleafia Health Inc. described in the joint press release issued by Emblem and Aleafia on December 19, 2018, as well as certain other Meeting matters as set out in the Circular mailed to shareholders. The Cannabis Investor
iAnthus and MPX Bioceutical Announce Closing of $1.6 Billion Business Combination: iAnthus Capital Holdings, Inc. (CSE: IAN, OTCQX: ITHUF) and MPX Bioceutical Corporation (CSE: MPX) (OTCQX: MPXEF) are pleased to announce the closing of the previously announced plan of arrangement under the Business Corporations Act (British Columbia) pursuant to which iAnthus acquired all of the issued and outstanding common shares of MPX pursuant to the terms of an arrangement agreement, as amended, among, inter alia, iAnthus and MPX dated October 18, 2018.
“2019 will be a transformative year for iAnthus, with the closing of our business combination with MPX being a crucial step forward. As the U.S. cannabis market continues to expand with increasing consumer and regulatory acceptance, iAnthus will continue to execute and provide the quality products and brands that our customers demand. As demonstrated with our 2018 acquisitions in Florida and New York, and now with the closing of our MPX transaction, the iAnthus team continues to demonstrate its focus on growing its platform and operations.” said Hadley Ford, CEO of iAnthus. The Cannabis Investor
Aphria Rejects Green Growth Brand’s Undervalued Hostile Takeover Bid: Aphria Inc. (TSX: APHA) (NYSE: APHA) today announced that its Board of Directors has rejected the hostile bid by Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) to acquire all of the outstanding common shares of the Company including any Common Shares that may become issued and outstanding after January 22, 2019, but prior to the expiry of the hostile bid upon the exercise, conversion or exchange of options, warrants, debentures or other securities of the Company exercisable or convertible into Common Shares, other than Common Shares owned by GGB or its affiliates, in exchange for 1.5714 shares of GGB. The Cannabis Investor
Green Growth Brands Responds to Rejected Hostile Takeover Bid of Aphria: Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) is providing comment with respect to Aphria Inc.’s (TSX: APHA) (NYSE: APHA) board of directors’ rejection of GGB’s offer to acquire all of the issued and outstanding common shares of Aphria. GGB continues to believe in the opportunity to combine the two businesses and benefit both groups of shareholders.
The combined entity of Aphria and GGB would create an unparalleled North American player with both Canadian and U.S. operations. GGB’s Offer is one way to combine these businesses across borders, while creating significant value for shareholders of both companies. The Cannabis Investor
Namaste Technologies Board Fires CEO Sean Dollinger and Launches Strategic Review: Namaste Technologies Inc. (TSXV: N) (FRANKFURT: M5BQ) (OTCQB: NXTTF) announced today that, following a recent expression of interest in the Company, the Board of Directors of the Company has launched a strategic review process to consider all value-maximizing alternatives.
Namaste also announced that following an investigation by a Special Committee of the Board of Directors, the Board has terminated the employment of Sean Dollinger as Chief Executive Officer of the Company for cause and removed him from his position as Director, effective immediately. Meni Morim has been appointed Interim CEO of the Company. To help strengthen our strategic partnerships, the Company has also appointed Darren Gill as Chief Strategy Officer. The Cannabis Investor
TransCanna Enters into Real Estate Option to Acquire 196,000 Sq Ft, Fully Enclosed Cannabis Facility on 6.5 Acres of Land: TransCanna Holdings Inc.(CSE: TCAN) (FSE: TH8) is pleased to announce that on February 1st the Company accepted an assignment of a real estate option agreement from its CEO, Jim Pakulis, to acquire a land, building and asset package which includes an existing 196,000 square foot facility on 6.5 acres of land, as well as cannabis packaging and processing equipment. The purchase price for the Property, should the option for purchase be exercised, is an aggregate of US$15 million payable in cash. Approximately US$8 million in tenant improvements has been completed over the past two years creating a vertically integrated cannabis facility. The Cannabis Investor
Aleafia Health to Ramp Up Research Division with Appointment of Product Data Science Fellow: Aleafia Health Inc. (TSXV: ALEF) (OTCQX: ALEAF) (FRA: ARAH), has appointed Dr. Graham Merry, as the Company’s first Product Data Science Fellow. Leveraging the Company’s proprietary 10 million point medical cannabis patient dataset, Dr. Merry will lead Aleafia Health’s ongoing medical cannabis research. These efforts will be aimed at developing evidence-based, proprietary treatment methods and products for chronic illnesses including pain, insomnia, anxiety and eating disorders.
Aleafia Health generated $0.6 million in research revenue in Q3 2018 alone, fuelled primarily by medical cannabis companies subscribing to Aleafia Health’s proprietary medical cannabis patient dataset. Aleafia Health tracks all patient interactions with referring doctors, nurse practitioners and educators from diagnosis, treatment, monitoring, and continuous learning. The highly differentiated medical cannabis patient big data leverages an enterprise-wide proprietary platform data set on Amazon AWS with market leading data visualization and business insights tools powered by Google Data Studio. These tools are uniquely configured based on over 50,000 unique patients. The Cannabis Investor
Weekend Unlimited Wins POT Ticker Symbol Lottery: Weekend Unlimited Inc. (CSE: YOLO) (OTCPK: WKULF) (FSE: 0OS1) has been informed by the Canadian Stock Exchange (CSE) that it has won the lottery for the trading symbol POT.
“Weekend Unlimited is thrilled to add the iconic POT trading symbol to its identity,” said Mr. Paul Chu, Weekend Unlimited President and CEO. “As a fast-growing multi-state operator, Weekend Unlimited is developing lifestyle brands around recreational and wellness to help define the future of the cannabis industry. The POT symbol is a tremendous fit with our brand identity.” The Cannabis Investor
Liberty Health Secures GMP Certification for 10,000 Square Feet at Liberty 360 Innovation Campus: Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF), a provider of high quality cannabis, announced today that The British Standards Institution (BSI) has awarded a Good Manufacturing Practice (GMP) certificate to Liberty Health Sciences medical cannabis manufacturing facility, located at Liberty 360 Innovation Campus property in Gainesville, FL. Certification for this facility indicates that it also meets all of the Florida Department of Health (DOH) requirements pertaining to the processing, extraction and production of medical cannabis.
“Receiving GMP certification at an additional facility is a major milestone for Liberty Health Sciences and it demonstrates our commitment to producing the highest quality and safest products possible for our customers throughout the state of Florida,” said George Scorsis, CEO of Liberty Health Sciences. “This achievement reflects the incredibly high standards we expect of ourselves and that our clients expect as a patient provider. We will continue to produce the highest quality products and exceed production standards that surpass even the most stringent regulatory requirements.” The Cannabis Investor
Aphria Transfers First Cannabis Strains to be Produced in Europe with Export to Danish Partner: Aphria Inc. (TSX: APHA) (NYSE: APHA) has completed its first transfer of plant cuttings from four of the Company’s cannabis strains to Denmark-based Schroll Medical, as part of the Company’s previously announced Strategic Partnership with Schroll. The shipment was completed under permits issued by the relevant health authorities, including an export permit from Health Canada, an import permit from the Danish Medicines Agency and a phytosanitary certificate from the Canadian Food Inspection Agency.
“We are pleased to introduce the first four Aphria strains to be produced in Europe, through our strategic alliance with Schroll,” said Hendrik Knopp, Managing Director of Aphria Germany, who is overseeing the Partnership on behalf of Aphria and Schroll. “This marks another important milestone for Aphria as we extend our leadership position in the European market, and it gives me joy to be able to say today that we literally have a good thing growing in Europe.” The Cannabis Investor
Supreme Cannabis Announces Trading Date on the Toronto Stock Exchange: Supreme Cannabis (TSXV: FIRE) (OTCQX: SPRWF) announced that its listed securities are expected to commence trading on the TSX on February 4, 2019. At that time, Supreme Cannabis’ common shares and 6.0% senior unsecured convertible debentures due 2021 will be voluntarily delisted from the TSX Venture Exchange and will commence trading on the TSX under the symbols “FIRE” and “FIRE.DB”, respectively. www.prnewswire.com
1933 Industries Provides an Update Regarding its Cannabis Cultivation Facility in Las Vegas: 1933 Industries Inc. (CSE: TGIF) (OTCQX: TGIFF) a licensed cultivator and producer of cannabis flower and concentrates and manufacturer of hemp/CBD wellness products, reports that construction on its new cultivation facility in Las Vegas is nearing completion and awaiting electrical meter installation.
The new facility will house the Company’s subsidiary, Alternative Medicine Association’s (“AMA”) indoor cannabis cultivation. AMA is one of Nevada’s largest wholesalers of cannabis products, including branded flower, wholesale distillate for vape products, and a broad range of concentrates with distribution channels in place throughout Nevada. PR Newswire
Canopy Rivers Announces Investment From Canopy Growth and Bought Deal Financing for Total of $85 Million: Canopy Rivers (TSXV: RIV) (OTCPK: CNPOF) has entered into an agreement with a syndicate of underwriters under which they have agreed to purchase 11,500,000 subordinated voting shares on a “bought deal” basis at a price of $4.80 for gross proceeds of approximately $55.0 million. Concurrent with the bought deal, Canopy Growth (TSX WEED) (NYSE: CGC), the Company’s largest shareholder, will purchase a minimum of 6,250,000 Subordinated Voting Shares ($4.80) for additional gross proceeds of a minimum of approximately $30.0 million. Canopy Growth’s ownership interest in the Company will increase to approximately 27.3% of the issued and outstanding shares of the Company on a non-diluted basis. The combined gross proceeds to the Company under the Offering will be a minimum of approximately $85 million. The Company intends to use the net proceeds from the Offering for follow-on investments in existing portfolio companies, new domestic and international investments, working capital and general corporate purposes. globenewswire.com
FSD Pharma Announces Signing of LOI with Solarvest to Develop and Test Pharma-Grade Cannabinoids out of Algae: FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) and Solarvest BioEnergy Inc. (TSXV: SVS) have signed a non-binding letter of intent. The parties intend to enter into a definitive agreement, under which Solarvest would conduct research using its algal expression technology to develop pharma-grade cannabinoids, and Solarvest would grant FSD Pharma an exclusive license over a subset of the Project Cannabinoids and certain royalty rights over all of the other Project Cannabinoids. businesswire
Emerald Health Therapeutics Secures Proprietary Extraction Technology and Extraction Capabilities in Agreement with Indena: Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) has entered into a license with Indena S.p.A. of Milan, Italy, bearing certain exclusivity rights in Canada to use Indena’s cannabidiol extraction technology, and contract manufacturing services for CBD extraction. In addition, Emerald has obtained exclusive use of Indena’s proprietary Phytosome technology for the purpose of developing novel cannabinoid-based products with superior utility, subject to a minimum volume agreement. This collaboration leverages Indena’s decades-long global presence in the plant extraction industry and botanical experience in phytochemical research. Globenewswire.com
Cronos Stock Downgraded After Rocketing More Than 100% in 2019 So Far: Cronos Group (TSX: CRON) (NASDAQ: CRON) shares were down 6%, after GMP Securities lowered its rating to hold from buy and reiterated a stock price target of C$24 ($18) that implies 21% downside from its current trading level. “The company’s shares have surged ~110% year-to-date on no material news and have outperformed the HMMJ cannabis index by a factor of 2,” analyst Martin Landry wrote in the note. “This strong performance forces us to change our rating to HOLD solely based on valuation.” GMP is a believer in the’ promising outlook at Cronos, praising its strong management team and record of efficient capital deployment. The recent news of tobacco giant Altria Inc.’s (NYSE: MO) planned C$2.4 billion investment in the company “will be a game changer,” Landry wrote in a note. However, “Cronos is still in the early stage of its development with limited revenues in relation to its sizable market cap,” said Landry. “Hence, in our view, the company needs to backfill its valuation with capital deployment into the U.S. market, increase its penetration in the Canadian recreational market and continue its international expansion.” Marketwatch
Zenabis Enters into Supply Agreement with Shoppers Drug Mart: Zenabis Global Inc. (TSXV: ZENA) announced that it has entered into a supply agreement with Shoppers Drug Mart. Shoppers may purchase dried marijuana and cannabis oil (once Zenabis receives its licence to sell oil) from the Zenabis medical branded product line, subject to any and all regulations. Shoppers also has the right to purchase all future products available as laws and regulations allow. Zenabis branded medical cannabis products will then be sold online at cannabis.shoppersdrugmart.ca, as regulations do not allow the sale of medical cannabis in retail pharmacies. www.newswire.ca
Origin House Signs Exclusive Distribution Agreement with Humboldt’s Finest and Provides Strategic Investment for Brand Acceleration: CannaRoyalty Corp. d/b/a Origin House (CSE: OH) (OTCQX: ORHOF) announced that that the Company has entered into an agreement to provide strategic financing of US$704,000 to Humboldt’s Finest, an alliance of heritage cannabis farms representing Humboldt County. Humboldt’s Finest produces sun-grown cannabis flower on their farms in Humboldt County, California, which is processed into products including jarred flower, pre-roll flower joints, live resin dabs/jars and/or live resin cartridges. The funds have been advanced towards the forward purchase of Humboldt’s Finest cannabis and cannabis products at a discount to the wholesale price. In conjunction with the Agreement, Origin House’s wholly-owned distribution subsidiary, RVR Distribution has renewed and extended its exclusive distribution rights to Humboldt’s Finest products. www.newswire.ca
Image source: Shutterstock
The Cannabis Investor is a leading media outlet for Cannabis investment opportunities and breaking industry news.
Join our text message list:
USA: Text potstocks to 313131 to join
CDN: Text potstocks to 393939 to join
Join our email list here: http://eepurl.com/bUSa71
Follow The Cannabis Investor on Social Media